Table 1.
Study ID | Country | Total N | % Female | Mean age | BMI, mean (SD) | Participant inclusion criteriab | Control N |
---|---|---|---|---|---|---|---|
Control group category A (Leaflet/advice only and/or non-weight-related follow‐up) | |||||||
Bertz 2012 17 | Sweden | 68 | 100% | 32 | 30.2 (3.4) | Women 8‐12 weeks post‐partum | 17 |
Fitzgibbon 2010 18 | USA | 213 | 100% | 46 | 39.8 (5.8) | African‐American women | 106 |
Foster‐Schubert 2012 19 | USA | 439 | 100% | 58 | 30.7 (3.9) | Post‐menopausal women | 87 |
Jeffrey and Wing 1995 20, c | USA | 202 | 50% | 37 | 31.1d | 40 | |
Jolly 2011 21 | UK | 640 | 71% | 49 | 33.9 (4.4) | 100 | |
Kuller 2012 22 | USA | 508 | 100% | 57 | 30.9 (3.8) | Post‐menopausal women | 255 |
Nanchahal 2011 23 | UK | 381 | 73% | 49 | 33.9 (5.6) | 190 | |
Patrick 2011 24 | USA | 441 | 0% | 44 | 34.3 (4.0) | Men | 217 |
Rejeski 2011 25 | USA | 288 | 67% | 67 | 32.6 (3.5) | Older adults, evidence of CVD or metabolic syndrome, self‐reported mobility limitation | 93 |
Silva 2010 26 | Portugal | 239 | 100% | 38 | 31.3 (4.0) | Pre‐menopausal women | 116 |
Stevens 1993 27 | USA | 564 | 79% | 43 | 29.5 (2.8) | Baseline blood pressure in high normal range | 256 |
Stevens 2001 28 | USA | 1191 | 34% | 43 | 30.9 (3.2) | As above | 596 |
Vissers 2010 29 | Belgium | 79 | NR | 45 | 30.8 (3.4) | 21 | |
Control group category B (Single weight management session) | |||||||
Appel 2011 30 | USA | 415 | 64% | 54 | 36.8 (5.1) | One or more CVD risk factors | 138 |
Eriksson 2009 31 | Sweden | 151 | 57% | 54 | 29.4 (5.1) | Additional risk factor for type 2 diabetes | 76 |
Hersey 2012 32 | USA | 1755 | 74% | NR | 33.6e | 598 | |
Lindstrom 2003 33 | Finland | 522 | 67% | 55 | 31.1 (4.5) | High risk for type 2 diabetes | 257 |
Mensink 2003 34 | Netherlands | 114 | 43% | 57 | 29.3 (3.1) | Elevated fasting glucose | 59 |
Morgan 2011 35 | Australia | 65 | 0% | 36 | 30.5 (3.0) | Men | 31 |
Penn 2009 36 | UK | 102 | 60% | 57 | 33.5 (4.6) | Impaired glucose tolerance | 51 |
Ross 2012 37 | Canada | 490 | 71% | 52 | 32.0 (4.2) | 208 | |
Vermunt 2011 38 | Netherlands | 925 | 60% | 58 | 28.5 (4.1) | Elevated risk of developing type 2 diabetes | 444 |
Control group category C (Seeing a professional without specific training) | |||||||
Dale 2008 39 | New Zealand | 79 | 67% | 46 | 36.5 (4.3) | Impaired insulin sensitivity | 23 |
DPP 40 | USA | 2161 | 69% | 50 | 34.2 (6.7) | Impaired glucose tolerance | 1082 |
Heshka 2006 41 | USA | 433 | 82% | 45 | 33.6 (3.7) | 212 | |
Jebb 2011 42 | UK, Germany, and Australia | 772 | 87% | 47 | 31.3 (2.6) | 395 | |
Munsch 2003 43 | Switzerland | 122 | 75% | 46 | 32.6 (1.8) | 17 | |
Rock 2010 44 | USA | 442 | 100% | 44 | 34.0 (3.2) | Women | 111 |
Villareal 2011 45 | USA | 107 | 63% | 70 | 37.3 (4.7) | Aged 65 years or older, mild to moderate frailty | 27 |
Wadden 2011 46 | USA | 261 | 80% | 52 | 39.0 (4.8) | Have ≥ 2 criteria for metabolic syndrome | 130 |
NR: not reported.
Beyond being adults of both genders with overweight/obesity.
Did not contribute to weight change analyses due to insufficient data.
SD not available.
Across all arms, SD not available.